Cognition Therapeutics (CGTX) vs Eloxx Pharmaceuticals (ELOX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cognition Therapeutics is the larger company by market cap ($55.4 million vs $43.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | ELOX |
|---|---|---|
| Share price | $0.5822 | $10.69 |
| Market cap | $55.37M | $43.69M |
| 1-day change | -3.06% | -1.75% |
| YTD return | -56.87% | — |
| 1-year return | -58.12% | — |
| 5-year return | -93.47% | — |
| P/E ratio (TTM) | — | 5.63 |
| EPS (TTM) | $-0.16 | $1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-23.49M | $-6.00M |
| 52-week high | $1.81 | $23.40 |
| 52-week low | $0.55 | $8.20 |
| Distance from 52-week high | -67.83% | -54.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +471.97% | +257.81% |
| Average volume | 464.94K | 28.48K |
| Shares outstanding | 95.10M | 4.09M |
| Employees | 14 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
CGTX vs ELOX FAQ
Which is bigger, Cognition Therapeutics or Eloxx Pharmaceuticals?
Cognition Therapeutics (CGTX) is larger, with a market capitalization of $55.37M compared with $43.69M for Eloxx Pharmaceuticals (ELOX).
Are Cognition Therapeutics and Eloxx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.